1. Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia.
- Author
-
Zakalashvili, Mamuka, Zarkua, Jaba, Zangurashvili, Lela, Kankia, Nino, Jashiashvili, Nino, Lomidze, Maka, Telia, Tengiz, Kerashvili, Vakhtang, Zhamutashvili, Maia, Abramishvili, Nikoloz, Rtskhiladze, Irakli, Metreveli, David, Weizenegger, Michael, Bartel, Jan, Raabe, Monika, Hedskog, Charlotte, Chodavarapu, Krishna, Brainard, Diana M., McHutchison, John G., and Mo, Hongmei
- Subjects
HEPATITIS C prevention ,NUCLEOTIDE sequencing ,RECOMBINANT DNA ,PHYLOGENY - Abstract
Abstract: Background and Aims: This study aimed to evaluate the prevalence of the hepatitis C virus intergenotype recombinant strain RF1_2k/1b in Georgia, confirm viral recombination by full genome sequencing, and determine a genetic relationship with previously described recombinant hepatitis C viruses. Methods: We retrospectively analysed data from 1421 Georgian patients with chronic hepatitis C. Genotyping was performed with the INNO‐LiPA VERSANT HCV Genotype 2.0 Assay. Results: Virus isolates were assigned to nonspecific hepatitis C genotypes 2a/2c (n = 387) as performed by sequencing of core and NS5B genes. Subsequently, sequencing results classified the core region as genotype 2k and the NS5B region as genotype 1b for 72% (n = 280) of genotype 2 patients, corresponding to 19.7% of hepatitis C patients in Georgia. Eight samples were randomly selected for full genome sequencing which was successful in 7 of 8 samples. Analysis of the generated consensus sequences confirmed that all 7 viruses were 2k/1b recombinants, with the recombination breakpoint located within 73‐77 amino acids before the NS2‐NS3 junction, similar to the previously described RF1_2k/1b virus. Phylogenetic analysis revealed clustering of the Georgian 2k/1b viruses and RF1_2k/1b, suggesting that they are genetically related. Conclusions: The 19.7% prevalence of RF1_2k/1b in Georgia patients is far higher than has generally been reported to date worldwide. Identification of recombinants in low income countries with a high prevalence of HCV infection might be reasonable for choosing the most cost‐effective treatment regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF